[Lovastatin. A new drug for the treatment of hypercholesterolemia].
Thirteen patients with Hypercholesterolemia were selected for therapy with the new lipid-reducing agent LOVASTATIN The most important criterion for entrance was total cholesterol values over 250 mg/dl in spite of an appropriate diet. The initial dose was 20 mg daily. The patients were re-examined at four weeks intervals and the dose was increased in those with total cholesterol values over 200 mg/dl. In each re-examination they had a complete physical and determination of multiple laboratory parameters. Therapy with LOVASTATIN was effective. The total cholesterol levels decreased by 31% and LDL--cholesterol decreased by 40%. There were no significant changes in the levels of triglycerides or HDL-cholesterol. No important toxicity or side effects were associated with the use of this medication.
Abouganem
D
D
Servicio de Endocrinología, Centro Médico Paitilla.
Núñez
P
P
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000378:metabolism; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008148:Lovastatin / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D002784:Cholesterol; D008148:Lovastatin
Lovastatina. Nuevo medicamento en el tratamiento de la hipercolesterolemia.